Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Brian Slomovitz, MD, regarding the long term follow-up data on PARP inhibitors in ovarian cancer

Dr. Slomovitz, Professor of Obstetrics & Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, considers the implications of the long term follow-up data on PARP inhibitors in ovarian cancer

Tags: Ovarian

Published: 17 November 2020

Recent Videos: Ovarian

video

Brian Slomovitz, MD, regarding the long term follow-up data on PARP inhibitors in ovarian cancer

Dr. Slomovitz, Professor of Obstetrics & Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, considers the implications of the long ...

video

Brian Slomovitz, MD, elaborates on the role of immunotherapy in ovarian cancer

Dr. Slomovitz, Professor of Obstetrics & Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, discusses the role of immunotherapy in ...

video

Brian Slomovitz, MD, offers opinion on the repeat use of PARP inhibitors

Dr. Slomovitz, Professor of Obstetrics & Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, considers whether an ovarian cancer patient ...

video

Brian Slomovitz, MD, on incorporating biomarker-driven therapy in ovarian cancer

Dr. Slomovitz, Professor of Obstetrics & Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, considers whether it is time to ...

video

BJ Rimel, MD, considers the challenges associated with genetic counseling

Dr. Rimel, Assistant Professor, Obstetrics and Gynecology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, considers the challenges associated with ...

video

BJ Rimel, MD, provides opinion on genetic counseling as a standard operating procedure

Dr. Rimel, Assistant Professor, Obstetrics and Gynecology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides opinion on whether genetic ...

video

BJ Rimel, MD, regarding the MAGENTA study and the role of genetic counseling

Dr. Rimel, Assistant Professor, Obstetrics and Gynecology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, tells us about the outcomes ...

video

Robert L. Coleman, MD, FACOG, FACS, on the role of HRD in the management of ovarian cancer

Dr. Coleman, Chief Scientific Officer, US Oncology Research, offers opinion on differentiating between PARP inhibitors in the management of ovarian ...

video

Robert L. Coleman, MD, FACOG, FACS, tells us about the negative outcomes from the IMagyn050 study

Dr. Coleman, Chief Scientific Officer, US Oncology Research, tells us about the negative outcomes from the IMagyn050/GOG 3015/ENGOT-OV39 Phase III ...

video

Robert L. Coleman, MD, FACOG, FACS, shares his impressions of the SOLO-1 update from ESMO 2020

Dr. Coleman, Chief Scientific Officer for US Oncology Research, shares his impressions of the SOLO-1 update investigating olaparib in ...

Related Videos

video-image

Brian Slomovitz, MD, elaborates on the role of immunotherapy in ovarian cancer

video-image

Brian Slomovitz, MD, offers opinion on the repeat use of PARP inhibitors

video-image

Brian Slomovitz, MD, on incorporating biomarker-driven therapy in ovarian cancer

video-image

BJ Rimel, MD, considers the challenges associated with genetic counseling

video-image

BJ Rimel, MD, provides opinion on genetic counseling as a standard operating procedure

video-image

BJ Rimel, MD, regarding the MAGENTA study and the role of genetic counseling

video-image

Robert L. Coleman, MD, FACOG, FACS, shares his impressions of the SOLO-1 update from ESMO 2020

video-image

Robert L. Coleman, MD, FACOG, FACS, on the role of HRD in the management of ovarian cancer

video-image

Robert L. Coleman, MD, FACOG, FACS, tells us about the negative outcomes from the IMagyn050 study

video-image

Thomas Herzog, MD, discusses the application of the PRIMA and PAOLA results in clinical practice

video-image

Thomas Herzog, MD, explains the importance of "weights and plates" in the PRIMA clinical trial

video-image

Thomas Herzog, MD, elaborates on his approach to BRCA and HRD testing

video-image

Thomas Herzog, MD, considers the use of a PARP in a patient that failed first line PARP therapy

video-image

Case Study: High-Grade Serous Ovarian Cancer Recurrence

video-image

Case Study: COVID-19 and Ovarian Cancer

video-image

Case Study: High-Grade Serous Ovarian Cancer Recurrence - Surgery vs. Chemotherapy

video-image

Case Study: Platinum Sensitive Recurrent High-Grade Serous Ovarian Cancer

video-image

Dana Chase, MD, FACOG, shares thoughts on the role of I-O in GTT management

video-image

Dana Chase, MD, FACOG, provides thoughts on the clinical evidence of secondary cytoreductive surgery

video-image

Dana Chase, MD, FACOG, on interpretations of the overall survival results of the Phase 3 SOLO2 study

video-image

Dana Chase, MD, FACOG, summarizes the outcomes of the NRG-GY004 phase III study in ovarian cancer

video-image

Andres Poveda, MD, considers the role of PARP inhibitors in advanced ovarian cancer

video-image

Andres Poveda, MD, discusses the BRCA mutation and homologous recombination deficiency

video-image

Andres Poveda, MD, shares design and outcomes of the PHASE 3 SOLO2 regarding ovarian cancer

video-image

Dana Chase, MD, FACOG, considers the role of PARP inhibitors in advanced ovarian cancer today

video-image

Dana Chase, MD, FACOG, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

video-image

Joyce Liu, MD, provides perspective on the large studies in advanced ovarian cancer

video-image

Joyce Liu, MD, on overall survival outcomes of Phase 3 SOLO2 study regarding advanced ovarian cancer

video-image

Joyce Liu, MD, shares thoughts on the activity of the Wee1 inhibitor as monotherapy in USC

video-image

Joyce Liu, MD, provides good news, in spite of Phase 3 NRG-GY004 study being negative

video-image

Joyce Liu, MD, summarizes the outcomes of the NRG-GY004 phase III study regarding ovarian cancer

video-image

Joyce Liu, MD, provides background and design of the NRG-GY004 phase III study regarding ovarian cancer

video-image

Robert Coleman, MD, FACOG, FACS, describes the overall survival outcomes of the Phase 3 SOLO2 clinical study

video-image

Robert Coleman, MD, FACOG, FACS, explains the underlying biology of homologous recombination deficiency

video-image

Robert Coleman, MD, FACOG, FACS, discusses the 2 recent FDA approvals for PARP inhibitors in ovarian cancer

video-image

Robert Coleman, MD, FACOG, FACS, provides thoughts on the NRG-GY004 phase III study

video-image

Robert Coleman, MD, FACOG, FACS, shares conclusions that can be drawn from phase 3 GOG213 study at ASCO20

video-image

Karen Lu, MD, discusses how PARP inhibitors have changed the management of advanced ovarian cancer

video-image

Karen Lu, MD, illustrates challenges the MAGENTA study brings up associated with genetic counseling

video-image

Karen Lu, MD, provides opinion on whether genetic counseling should be part of the SOP for breast and ovarian cancer risk

video-image

Karen Lu, MD, shares outcomes of the MAGENTA study investigating the role of genetic counseling

video-image

Karen Lu MD, elaborates on the underlying biology of homologous recombination deficiency (HRD) and how it applies to ovarian cancer management

video-image

Robert L. Coleman, MD, FACOG, FACS, on takeaways from the ovarian plenary session at ESMO '19

video-image

Robert L. Coleman, MD, FACOG, FACS, on how veliparib factors into ovarian cancer treatment

video-image

David Gershenson, MD, on considerations for maintenance therapy in ovarian cancer

video-image

David Gershenson, MD, elaborates on the role of MEK inhibitor trametinib in LGSC

video-image

Michael J. Birrer, MD, PhD, considers the benefits of various PARP inhibitors in ovarian cancer

video-image

Michael J. Birrer, MD, PhD, regarding BRCA status in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, on the role of maintenance therapy in newly diagnosed ovarian cancer

video-image

Michael J. Birrer, MD, PhD, elaborates on the outcomes from the FORWARD I study

video-image

Michael Birrer, MD, on the key takeaways from the ovarian plenary session in ovarian cancer at ESMO 2019

video-image

Joanie Mayer Hope, MD, on how Any Mountain is supporting women with ovarian cancer